Nanocarrier-Based Targeted Therapies for Myocardial Infarction.
Nanocarrier-Based Targeted Therapies for Myocardial Infarction.
复制标题
基于纳米载体的心肌梗死靶向治疗。
DOI：
10.3390/pharmaceutics14050930
复制
发表时间：
2022-04-25
期刊：
影响因子：
5.4
通讯作者：
Lundy, David J.
中科院分区：
文献类型：
--
作者：
George, Thomashire A.;Hsu, Chuan-Chih;Meeson, Annette;Lundy, David J.
心肌梗死是世界范围内发病率和死亡率的主要原因。由于成年哺乳动物心肌固有的再生差和有效药物递送的挑战，再生治疗进展甚微。纳米载体，包括脂质体、纳米颗粒和外泌体，为心肌梗死的治疗提供了许多潜在的优势，包括改善治疗剂的递送、保留和延长活性。然而，有许多挑战阻碍了这些技术的广泛临床应用。本文旨在总结该领域的重要原理和发展，重点是基于配体或基于细胞模拟的靶向纳米载体。最后，讨论了局限性和潜在的未来方向。
Myocardial infarction is a major cause of morbidity and mortality worldwide. Due to poor inherent regeneration of the adult mammalian myocardium and challenges with effective drug delivery, there has been little progress in regenerative therapies. Nanocarriers, including liposomes, nanoparticles, and exosomes, offer many potential advantages for the therapy of myocardial infarction, including improved delivery, retention, and prolonged activity of therapeutics. However, there are many challenges that have prevented the widespread clinical use of these technologies. This review aims to summarize significant principles and developments in the field, with a focus on nanocarriers using ligand-based or cell mimicry-based targeting. Lastly, a discussion of limitations and potential future direction is provided.
登录
查看更多内容
影响因子：
10
作者：
Cheng, Bill;Toh, Elsie K. W.;Hsieh, Patrick C. H.
通讯作者：
Hsieh, Patrick C. H.
影响因子：
10.8
作者：
Chang, Ming-Yao;Yang, Yu-Jen;Hsieh, Patrick C. H.
通讯作者：
Hsieh, Patrick C. H.
影响因子：
5.4
作者：
Antimisiaris SG;Mourtas S;Marazioti A
通讯作者：
Marazioti A
影响因子：
3.1
作者：
Boyle AJ;Hwang J;Ye J;Shih H;Jun K;Zhang Y;Fang Q;Sievers R;Yeghiazarians Y;Lee RJ
通讯作者：
Lee RJ
DOI：
10.1016/j.jconrel.2015.06.017
发表时间：
2015-12-28
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Dasa SSK;Suzuki R;Gutknecht M;Brinton LT;Tian Y;Michaelsson E;Lindfors L;Klibanov AL;French BA;Kelly KA
通讯作者：
Kelly KA